TRIUMPH-4 participants lost 28.7% of their body weight on average at the 12mg weekly dose over 68 weeks, with the 9mg arm producing 26.4%. Absolute weight loss averaged 32.3 kg (71.2 lbs) at 12mg and 29.1 kg (64.2 lbs) at 9mg. Placebo produced 2.1% loss. These numbers are the strongest weight loss results ever reported for an obesity pharmacotherapy.
Real-world weight loss will be lower than these trial figures. Data from semaglutide and tirzepatide shows that post-approval average weight loss runs approximately 60–75% of trial-reported values. Applied to retatrutide, that projects 17–22% average real-world loss at 12mg, or roughly 34–43 lbs for a 200 lb starting weight. Highly adherent individuals can still match trial figures, but population averages always drop.
This article covers the Phase III numbers in detail, projections by starting weight and dose, the time course of weight loss through treatment, and why real-world outcomes differ from trial outcomes. Retatrutide is investigational and not yet approved, so these projections describe what approval-era use is likely to produce based on the evidence base.
What drives weight loss on retatrutide
Retatrutide activates three receptors simultaneously: GLP-1, GIP, and glucagon. Each contributes to weight loss through a different mechanism. GLP-1 activity slows gastric emptying and increases satiety, reducing caloric intake. GIP activity improves the metabolic profile and adds efficacy without much safety cost. Glucagon receptor activity is the retatrutide innovation: it increases resting energy expenditure and promotes hepatic fat oxidation, so the body burns more calories at rest while also eating less.
The combined effect is what produces the step-change in efficacy over semaglutide (GLP-1 only) and tirzepatide (GLP-1 plus GIP). Semaglutide reduces intake. Tirzepatide reduces intake more and improves metabolic signalling. Retatrutide does both and increases expenditure on top. The Phase III data confirms that the three mechanisms combine rather than compete, producing weight loss beyond what either single or dual agonism has achieved.
Body fat loss accounts for the majority of weight loss in the TRIUMPH-4 trial. Phase II body composition data suggested approximately 85% of the total weight loss was fat mass and 15% lean mass, a pattern common to rapid weight loss at any scale.
What the trial data projects by starting weight
TRIUMPH-4 enrolled adults with obesity (BMI 30+) and knee osteoarthritis, with an average starting weight of approximately 113 kg (249 lbs). Applying the 28.7% reduction produces the 32.3 kg absolute loss figure. For individuals at different starting weights, the projection scales proportionally. The table below applies the 28.7% trial figure and a 22% realistic real-world estimate at 12mg across common starting weights.
| Starting Weight | Trial Avg (−28.7%) | Real-World Est (−22%) | Ending Weight (Real-World) |
|---|---|---|---|
| 180 lbs (82 kg) | −52 lbs | −40 lbs | 140 lbs |
| 200 lbs (91 kg) | −57 lbs | −44 lbs | 156 lbs |
| 220 lbs (100 kg) | −63 lbs | −48 lbs | 172 lbs |
| 250 lbs (113 kg) | −72 lbs | −55 lbs | 195 lbs |
| 280 lbs (127 kg) | −80 lbs | −62 lbs | 218 lbs |
| 320 lbs (145 kg) | −92 lbs | −70 lbs | 250 lbs |
Projections assume proportional response across starting weights, which holds within the BMI 30–45 trial enrolment range. Individual response varies considerably.
Time course of weight loss
Weight loss is not linear. The fastest loss occurs between months 3 and 9 after starting treatment, once the maintenance dose is reached and the body is responding to consistent receptor activation. Before month 3, weight loss during titration is modest (typically 3–5%). After month 9, the rate slows as participants approach their individual physiological plateau.
Typical time-course expectations based on TRIUMPH-4 and Phase II data: around 5% loss by week 16, 12–15% by week 32, 20–25% by week 52, and full plateau (26–29% depending on dose) by week 68. Individual variation is substantial and these figures describe the trial-population median. For full dosing context see the Retatrutide Dosage Guide.
A useful framing for the time course: expect weight loss to feel slow for the first three months (during titration), accelerate through months 4–9, and then gradually decelerate through months 10–16 as the plateau approaches. Missing doses during the acceleration phase has a disproportionate effect on total outcomes because that is when the drug is doing the most work.
Weight maintenance after plateau
Once weight loss plateaus around month 12–16, continued retatrutide treatment maintains the new weight. Discontinuation leads to gradual regain, because the drug is managing the underlying physiological drivers of weight (hunger signalling, gastric emptying, energy expenditure) rather than resetting them. Once the drug stops, the physiology reverts toward baseline.
Specific retatrutide withdrawal data has not been published yet. Semaglutide STEP 4 extension data showed approximately two-thirds of weight loss regained within 12 months of stopping. Tirzepatide SURMOUNT-4 showed a similar pattern, with about 14% body weight regained in the withdrawal arm after 52 weeks. Retatrutide will likely follow this pattern, with 50–70% of lost weight regained in the year following discontinuation.
Trial results versus real-world results
The gap between trial and real-world performance is the most important practical consideration. Semaglutide real-world data has shown average weight loss of approximately 10–12% against the STEP 1 trial figure of 14.9%, or about 67–80% of trial performance. Tirzepatide real-world data has shown similar patterns: 13–16% average against the 22.5% SURMOUNT-1 figure, or about 58–71% of trial performance.
Why the gap exists is worth understanding because it points at what individuals can do to approach trial figures. Trials enforce dose escalation on schedule; real-world use often stalls at lower doses because of side effects or cost. Trials provide structured nutritional and activity support; real-world use typically does not. Trials exclude participants unlikely to adhere; real-world use includes everyone. Trials run for a fixed period with 100% drug availability; real-world use suffers supply disruptions and insurance issues.
Individuals who want to approach trial figures can do so by controlling the adherence variables: complete the titration as scheduled, adhere to weekly dosing without gaps, maintain a moderate caloric deficit alongside the drug, and continue treatment for the full time-to-plateau period. The full safety profile matters here because tolerability drives adherence — covered in Retatrutide Side Effects.
Comparison with semaglutide and tirzepatide
Across the incretin-plus class, weight loss efficacy scales with the number of receptors activated. The table below pulls top-dose Phase III results for direct comparison.
| Compound | Mechanism | Trial Weight Loss | Real-World Est |
|---|---|---|---|
| Retatrutide 12mg | GLP-1 + GIP + Glucagon | −28.7% | 17–22% |
| Tirzepatide 15mg | GLP-1 + GIP | −22.5% | 13–17% |
| Semaglutide 2.4mg | GLP-1 | −14.9% | 10–12% |
| Liraglutide 3.0mg | GLP-1 (daily) | −8.0% | 5–7% |
The pattern is clean. Each mechanism step adds roughly 5–7 percentage points of weight loss. Real-world percentages run 60–75% of trial figures across all four compounds, suggesting the adherence gap is a class phenomenon rather than drug-specific. For the direct head-to-head detail see Retatrutide vs Tirzepatide and Retatrutide vs Semaglutide.
One practical implication: for most individuals, retatrutide 9mg will probably outperform tirzepatide 15mg in real-world use while producing a lower side effect profile than retatrutide 12mg. This is the comparison that is likely to matter most post-approval, not the trial-population headline figures.
Frequently asked questions
How much weight can you lose on retatrutide?
In Phase III TRIUMPH-4, participants lost 28.7% of body weight at the 12mg weekly dose over 68 weeks, averaging 32.3 kg (71.2 lbs) in absolute terms. The 9mg dose produced 26.4% loss, averaging 29.1 kg (64.2 lbs). These are trial-population averages and real-world results are typically 60-75% of trial figures due to adherence differences.
How does that compare with tirzepatide and semaglutide?
Retatrutide exceeds both. Tirzepatide's SURMOUNT-1 reported 22.5% at 15mg over 72 weeks, and semaglutide's STEP 1 reported 14.9% at 2.4mg over 68 weeks. The cross-trial comparison is indicative rather than head-to-head, but each receptor step (GLP-1, then GLP-1 plus GIP, then GLP-1 plus GIP plus glucagon) adds roughly 5-7 percentage points of weight loss.
How long does it take to see weight loss on retatrutide?
Weight loss typically begins in the first four weeks of treatment, during the 2mg starting dose period. Noticeable loss (5% of body weight) usually appears by weeks 12-16, around the time the maintenance dose is reached. Peak weight loss in the TRIUMPH-4 trial was reached between weeks 52 and 68, suggesting the full effect takes approximately 12-16 months.
What weight loss can someone starting at 200 lbs expect?
At the trial average of 28.7% reduction, a 200 lb (91 kg) starting weight projects to approximately 57 lbs (26 kg) of loss over 68 weeks at 12mg, ending around 143 lbs. Real-world averages of 60-75% of trial figures would project to 34-43 lbs of loss (17-21%), ending between 157-166 lbs. Individual response varies considerably.
Why do real-world results typically underperform trial results?
Clinical trials select for adherent participants, provide structured clinical support, and use standardised dose escalation. Real-world use introduces missed doses, slower titration due to side effects, shorter treatment duration, and less structured support. Semaglutide and tirzepatide real-world data show 60-75% of trial-reported weight loss on average, though highly adherent individuals can match trial figures.
Does weight loss plateau on retatrutide?
Weight loss plateaus for most participants around 12-16 months of treatment, which is the pattern observed in Phase III TRIUMPH-4. After the plateau, continued treatment maintains the weight loss; discontinuation leads to gradual regain. Semaglutide withdrawal data (STEP 4 extension) showed approximately two-thirds of weight loss was regained within 12 months of stopping.
How much weight is regained after stopping retatrutide?
Specific discontinuation data for retatrutide has not yet been published. Based on semaglutide and tirzepatide withdrawal data, expect approximately 50-70% of weight loss to be regained within 12 months of stopping treatment. This is why the compound is framed as chronic therapy rather than a time-limited intervention, similar to the approved GLP-1 class.
Can retatrutide cause too much weight loss?
Theoretically yes, though the stopping criteria in TRIUMPH trials managed this. Trial protocols typically pause or reduce dosing when participants approach clinically appropriate weight targets (BMI 22-25 depending on protocol). Once retatrutide is approved, clinical monitoring will include weight loss velocity and total loss, with dose adjustment or discontinuation considered for participants approaching underweight status.
This article is for informational and educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug. It has not been approved by the FDA, EMA, MHRA, or any other regulatory agency. Weight loss projections presented here are derived from clinical trial data and published real-world analyses of related compounds. Individual response varies considerably based on starting weight, adherence, diet, activity, and medical history. Projections are not guarantees. Consult a licensed healthcare provider before starting, stopping, or changing any medication. Peptide File reports on research and does not sell, prescribe, or recommend sources for any compound discussed.